Integer Holdings Co. (NYSE:ITGR) Given Average Recommendation of “Moderate Buy” by Analysts

Integer Holdings Co. (NYSE:ITGR) has earned a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $142.00.

A number of equities research analysts recently issued reports on the company. Citigroup raised their price target on Integer from $124.00 to $130.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 1st. Bank of America boosted their target price on shares of Integer from $135.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. KeyCorp raised their price target on shares of Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 15th. Wells Fargo & Company reissued an “overweight” rating and issued a $160.00 price objective on shares of Integer in a research report on Tuesday, December 3rd. Finally, Truist Financial reduced their target price on shares of Integer from $150.00 to $147.00 and set a “buy” rating on the stock in a research report on Friday, October 25th.

Hedge Funds Weigh In On Integer

Large investors have recently bought and sold shares of the business. Contravisory Investment Management Inc. lifted its position in shares of Integer by 55.9% during the third quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 80 shares during the last quarter. Huntington National Bank raised its stake in shares of Integer by 8,933.3% during the 3rd quarter. Huntington National Bank now owns 271 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 268 shares in the last quarter. Quest Partners LLC lifted its position in Integer by 3,688.9% during the second quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 332 shares during the last quarter. GAMMA Investing LLC boosted its stake in Integer by 60.9% in the second quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 142 shares in the last quarter. Finally, Innealta Capital LLC purchased a new position in Integer in the second quarter worth $110,000. Institutional investors own 99.29% of the company’s stock.

Integer Trading Up 0.1 %

ITGR stock opened at $139.39 on Monday. The firm’s fifty day simple moving average is $132.63 and its two-hundred day simple moving average is $125.17. The stock has a market capitalization of $4.68 billion, a price-to-earnings ratio of 43.02, a price-to-earnings-growth ratio of 2.02 and a beta of 1.12. The company has a quick ratio of 2.09, a current ratio of 3.28 and a debt-to-equity ratio of 0.67. Integer has a twelve month low of $86.42 and a twelve month high of $142.76.

Integer (NYSE:ITGR) last issued its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 EPS for the quarter, beating the consensus estimate of $1.36 by $0.07. The company had revenue of $431.42 million for the quarter, compared to the consensus estimate of $440.59 million. Integer had a net margin of 6.70% and a return on equity of 11.63%. The firm’s revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.27 EPS. As a group, analysts anticipate that Integer will post 5.33 earnings per share for the current year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.